Writer and former first daughter Chelsea Clinton will no longer serve on Clover Health’s board, according to an Oct. 31 news release. According to the company, Ms. Clinton was the longest-serving board member, having joined in early 2017. Oct. 31…
The Latest
Elevance Health said it is going all in on AI, but the tech’s potential risks in insurance have spurred recent regulations, signaling the public’s concern. Anita Allemand, PharmD, joined Elevance Health as chief growth officer earlier this year. She spoke…
Musculoskeletal (MSK) conditions now cost the U.S. more than $420 billion, yet many payer-led interventions fail to engage patients early enough to prevent low-value procedures and rising costs. This new report from TailorCare shows what happens when patients are guided…
Presented by:
Oregon Health & Science University runs 53 ORs across 4 sites and performs nearly 39,000 cases a year. With financial pressure and rising surgical volume, perioperative leaders needed a faster, more reliable way to staff rooms and sustain morale. This…
Presented by:
Regional anesthesia is moving from “nice to have” to a core component of orthopedic care by easing pain, accelerating recovery and expanding what’s possible in outpatient surgery. Yet many groups leave clinical and financial value on the table due to…
Presented by:
Nearly half of hospital revenue cycle leaders say denials are their top financial concern — outranking labor shortages, reimbursement cuts and analytics gaps. While many teams focus on rework, high-performing hospitals are looking upstream. This short report offers 10 strategies…
Presented by:
How proactive CFOs are protecting revenue, strengthening compliance, and preparing for sweeping Medicaid changes Q1 2026 is coming fast—and with it, Medicaid cuts, tighter margins, and new documentation and compliance requirements. Hospitals in ACA expansion states and rural communities face…
Presented by:
The Medicare Advantage (MA) market is entering a potentially transformative phase. Profit pressures, regulatory shifts, and an evolving reimbursement landscape are converging to prompt a strategic reset. A shift from growth-at-any-cost to profitability-first Like many publicly traded payors with significant…
Managing locum tenens at scale is rarely efficient. For one Mid-Atlantic academic medical center, a fragmented approach led to high costs, siloed departments and internal competition for providers. But a centralized, vendor-neutral strategy changed everything. By overhauling its locum tenens…
Presented by:
More than 200 industry leaders have spoken: the 2025 Trends in Specialty Drug Benefits Report, co-sponsored by Genentech and Pharmaceutical Strategies Group (PSG), is here. This executive summary captures how payers are resetting specialty drug strategies and what that means…
Presented by: